Terms: = Lung cancer AND IL6ST, CDw130, 3572, ENSG00000134352, P40189, IL6R-beta, GP130-RAPS, GP130, CD130 AND Treatment
23 results:
1. Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway.
Liu B; Zheng X; Li J; Yao P; Guo P; Liu W; Zhao G
BMC Cancer; 2023 Nov; 23(1):1070. PubMed ID: 37932661
[TBL] [Abstract] [Full Text] [Related]
2. The clinical relevance of OSM in inflammatory diseases: a comprehensive review.
Wolf CL; Pruett C; Lighter D; Jorcyk CL
Front Immunol; 2023; 14():1239732. PubMed ID: 37841259
[TBL] [Abstract] [Full Text] [Related]
3. Candidate Bevacizumab Biosimilar CT-P16 versus European Union Reference Bevacizumab in Patients with Metastatic or Recurrent Non-Small Cell lung cancer: A Randomized Controlled Trial.
Verschraegen C; Andric Z; Moiseenko F; Makharadze T; Shevnya S; Oleksiienko A; Yañez Ruiz E; Kim S; Ahn K; Park T; Park S; Ju H; Ohe Y
BioDrugs; 2022 Nov; 36(6):749-760. PubMed ID: 36169807
[TBL] [Abstract] [Full Text] [Related]
4. Repurposing Methotrexate in Dampening SARS-CoV2-S1-Mediated IL6 Expression: Lessons Learnt from lung cancer.
Gowda P; Patrick S; Joshi SD; Kumawat RK; Sen E
Inflammation; 2022 Feb; 45(1):172-179. PubMed ID: 34480250
[TBL] [Abstract] [Full Text] [Related]
5. PRMT5 Enables Robust STAT3 Activation via Arginine Symmetric Dimethylation of SMAD7.
Cai C; Gu S; Yu Y; Zhu Y; Zhang H; Yuan B; Shen L; Yang B; Feng XH
Adv Sci (Weinh); 2021 May; 8(10):2003047. PubMed ID: 34026434
[TBL] [Abstract] [Full Text] [Related]
6. FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment.
Song X; Tang W; Peng H; Qi X; Li J
Invest New Drugs; 2021 Oct; 39(5):1201-1212. PubMed ID: 33829354
[TBL] [Abstract] [Full Text] [Related]
7. NEK9, a novel effector of IL-6/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation.
Lu G; Tian S; Sun Y; Dong J; Wang N; Zeng J; Nie Y; Wu K; Han Y; Feng B; Shang Y
Theranostics; 2021; 11(5):2460-2474. PubMed ID: 33500736
[No Abstract] [Full Text] [Related]
8. Chidamide increases the sensitivity of Non-small Cell lung cancer to Crizotinib by decreasing c-
Ding N; You A; Tian W; Gu L; Deng D
Int J Biol Sci; 2020; 16(14):2595-2611. PubMed ID: 32792859
[No Abstract] [Full Text] [Related]
9. gp130 degradation induced by epirubicin contributes to chemotherapy efficacy.
Liu F; Jin H; Shen J; Wu D; Tian Y; Huang C
Biochem Biophys Res Commun; 2019 Nov; 519(3):572-578. PubMed ID: 31537377
[TBL] [Abstract] [Full Text] [Related]
10. Interaction between epidermal growth factor receptor and interleukin-6 receptor in NSCLC progression.
Yuquan B; Hexiao T; Laiyi W; Gaofeng P; Xuefeng Z; Ming X; Yanhong W; Li Z; Jinping Z
J Cell Biochem; 2019 Jan; 120(1):872-881. PubMed ID: 30132982
[TBL] [Abstract] [Full Text] [Related]
11. Plumbagin suppresses the human large cell lung cancer cell lines by inhibiting IL-6/STAT3 signaling in vitro.
Yu T; Xu YY; Zhang YY; Li KY; Shao Y; Liu G
Int Immunopharmacol; 2018 Feb; 55():290-296. PubMed ID: 29294439
[TBL] [Abstract] [Full Text] [Related]
12. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in cancer: Challenges and Opportunities.
Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
[TBL] [Abstract] [Full Text] [Related]
13. Innate Immune Cytokines, Fibroblast Phenotypes, and Regulation of Extracellular Matrix in lung.
Richards CD
J Interferon Cytokine Res; 2017 Feb; 37(2):52-61. PubMed ID: 28117653
[TBL] [Abstract] [Full Text] [Related]
14. IL6 Trans-signaling Promotes KRAS-Driven lung Carcinogenesis.
Brooks GD; McLeod L; Alhayyani S; Miller A; Russell PA; Ferlin W; Rose-John S; Ruwanpura S; Jenkins BJ
Cancer Res; 2016 Feb; 76(4):866-76. PubMed ID: 26744530
[TBL] [Abstract] [Full Text] [Related]
15. Percutaneous management of pulmonary metastases arising from colorectal cancer; a systematic review.
Lyons NJ; Pathak S; Daniels IR; Spiers A; Smart NJ
Eur J Surg Oncol; 2015 Nov; 41(11):1447-55. PubMed ID: 26358568
[TBL] [Abstract] [Full Text] [Related]
16. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Cao W; Liu Y; Zhang R; Zhang B; Wang T; Zhu X; Mei L; Chen H; Zhang H; Ming P; Huang L
Sci Rep; 2015 Jul; 5():8477. PubMed ID: 26166037
[TBL] [Abstract] [Full Text] [Related]
17. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
[TBL] [Abstract] [Full Text] [Related]
18. STAT3 is activated by JAK2 independent of key oncogenic driver mutations in non-small cell lung carcinoma.
Looyenga BD; Hutchings D; Cherni I; Kingsley C; Weiss GJ; Mackeigan JP
PLoS One; 2012; 7(2):e30820. PubMed ID: 22319590
[TBL] [Abstract] [Full Text] [Related]
19. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract] [Full Text] [Related]
20. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
Gao SP; Mark KG; Leslie K; Pao W; Motoi N; Gerald WL; Travis WD; Bornmann W; Veach D; Clarkson B; Bromberg JF
J Clin Invest; 2007 Dec; 117(12):3846-56. PubMed ID: 18060032
[TBL] [Abstract] [Full Text] [Related]
[Next]
